for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lonza partners with Anthos Therapeutics for thrombosis treatment

FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 26, 2019. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Lonza has signed a partnership agreement with Anthos Therapeutics, the Swiss company said on Thursday, to develop and manufacture an antibody treatment for blood clots.

Anthos, a biotech created by Blackstone Life Sciences and Novartis, will get access to Lonza’s drug substance, drug product and labeling/packaging services to speed the launch of Abelacimab, a treatment for patients at risk of thrombosis.

Reporting by John Revill; editing by Thomas Seythal

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up